



Synthetic Biologics, Inc.  
9605 Medical Center Drive, Suite 270  
Rockville, Maryland 20850

May 7, 2021

**VIA EDGAR**

U.S. Securities and Exchange Commission  
Division of Corporation Finance  
100 F Street, N.E.  
Washington, D.C. 20549  
Attention: Dillon Hagius

***Re: Synthetic Biologics, Inc.  
Registration Statement on Form S-3  
File No. 333-255726***

---

Ladies & Gentlemen:

Synthetic Biologics, Inc. (the "Company") hereby requests that the effective date of the Company's Registration Statement on Form S-3 (File No. 333-255726), be accelerated by the U.S. Securities and Exchange Commission to **Tuesday, May 11, 2021 at 5:00 pm**, New York City Time, or as soon as reasonably practicable thereafter.

The Company hereby authorizes Leslie Marlow and/or Patrick Egan of Gracin & Marlow, LLP to orally modify or withdraw this request for acceleration. Please contact Ms. Marlow at (516) 496-2223 or (212) 907-6457, or Mr. Egan at (914) 557-5574 with any questions you may have concerning this request, and please notify either of them when this request for acceleration has been granted.

Very truly yours,

Synthetic Biologics, Inc.

By: /s/ Steven A. Shallcross  
Name: Steven A. Shallcross  
Title: Chief Executive Officer and Chief Financial Officer

cc: Leslie Marlow, Esq., Gracin & Marlow, LLP  
Patrick Egan, Esq., Gracin & Marlow, LLP

---